Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in development phase under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
L 38 55 Collins St, Melbourne, Victoria, 3000
Website
www.mesoblast.com
Telephone
61 3 96396036
No of Employees
83
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MSB (ASX)
Revenue (2021)
$7.5M
-76.8%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-26.8%
(2021 vs 2020)
Market Cap*
$299.2M
Net Profit Margin (2021)
XXX
-446.8%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | RYONCIL |
| Remestemcel-L: | REVASCOR |
| Steroid-Refractory Acute Graft Versus Host Disease (Children) | |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Plans/Strategy | In December, the company announced its plans to conduct an additional US Phase 3 trial to support submissions for potential approval in both the US and EU. |
| 2021 | Contracts/Agreements | In December, the company agreed with OTAT for its proposal for pain reduction at 12 months as the primary endpoint of the next trial, with functional improvement and reduction in opioid use as secondary endpoints. |
| 2021 | Others | In November, the company refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. |
Competitor Comparison
| Key Parameters | Mesoblast Ltd | CSL Ltd | Regeneus Ltd | Acrux Ltd | Exopharm Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Melbourne | Pymble | Melbourne | Melbourne |
| State/Province | Victoria | Victoria | New South Wales | Victoria | Victoria |
| No. of Employees | 83 | 25,000 | - | 43 | - |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joseph R. Swedish | Chairman | Executive Board | 2019 | - |
| Silviu Itescu | Chief Executive Officer; Director; Managing Director | Executive Board | 2011 | - |
| Dagmar Rosa-Bjorkeson | Chief Operating Officer | Senior Management | 2021 | - |
| Eric Rose | Chief Medical Officer | Senior Management | 2022 | - |
| Andrew Chaponnel | Chief Financial Officer - Interim | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer